GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kindred Biosciences Inc (NAS:KIN) » Definitions » ROC (Joel Greenblatt) %

Kindred Biosciences (Kindred Biosciences) ROC (Joel Greenblatt) % : -108.63% (As of Jun. 2021)


View and export this data going back to 2013. Start your Free Trial

What is Kindred Biosciences ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Kindred Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2021 was -108.63%.

The historical rank and industry rank for Kindred Biosciences's ROC (Joel Greenblatt) % or its related term are showing as below:

KIN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -35158.33   Med: -921.39   Max: -62
Current: -123.81

During the past 9 years, Kindred Biosciences's highest ROC (Joel Greenblatt) % was -62.00%. The lowest was -35158.33%. And the median was -921.39%.

KIN's ROC (Joel Greenblatt) % is not ranked
in the Drug Manufacturers industry.
Industry Median: 7.85 vs KIN: -123.81

Kindred Biosciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 52.30% per year.


Kindred Biosciences ROC (Joel Greenblatt) % Historical Data

The historical data trend for Kindred Biosciences's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kindred Biosciences ROC (Joel Greenblatt) % Chart

Kindred Biosciences Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only -1,203.20 -639.58 -303.29 -211.66 -62.00

Kindred Biosciences Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 296.92 -141.44 -128.01 -112.85 -108.63

Competitive Comparison of Kindred Biosciences's ROC (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, Kindred Biosciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kindred Biosciences's ROC (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kindred Biosciences's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Kindred Biosciences's ROC (Joel Greenblatt) % falls into.



Kindred Biosciences ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Mar. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.337 + 0 + 3.225) - (1.521 + 0 + 1.372)
=2.669

Working Capital(Q: Jun. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.212 + 0 + 3.329) - (3.994 + 0 + 1.883)
=-1.336

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Kindred Biosciences for the quarter that ended in Jun. 2021 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2021 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2021  Q: Jun. 2021
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-34.176/( ( (30.676 + max(2.669, 0)) + (29.576 + max(-1.336, 0)) )/ 2 )
=-34.176/( ( 33.345 + 29.576 )/ 2 )
=-34.176/31.4605
=-108.63 %

Note: The EBIT data used here is four times the quarterly (Jun. 2021) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kindred Biosciences  (NAS:KIN) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Kindred Biosciences ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Kindred Biosciences's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kindred Biosciences (Kindred Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
1555 Bayshore Highway, Suite 200, Burlingame, CA, USA, 94010
Kindred Biosciences Inc is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. The company identifies targets that have already demonstrated safety and efficacy in humans and develop therapeutics based on these validated targets for dogs and cats. It has a pipeline of novel biologics in development across many therapeutic classes, alongside biologics manufacturing capabilities and a broad intellectual property portfolio.
Executives
Richard Chin director, officer: Chief Executive Officer C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Park West Asset Management Llc 10 percent owner 1 LETTERMAN DRIVE, SUITE C5-900, SAN FRANCISCO CA 94129
Denise Bevers director C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Wendy Wee officer: Chief Financial Officer C/O TELIK, INC. 700 HANSEN WAY PALO ALTO CA 94304
Hangjun Zhan officer: Chief Scientific Officer C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Ernest Mario director 20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Joseph S Mccracken director C/O NEXVET BIOPHARMA PLC, NATL INST, FOSTERS AVENUE, MOUNT MERRION, BLACKROCK L2 00000
Herbert D Montgomery director C/O ATKINSON 1001 BAYHILL DRIVE 2ND FL SAN BRUNO CA 94066
Raymond Townsend director C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Ervin Veszpremi director C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Stephen Sundlof officer: SVP of Regulatory Affairs C/O KINDRED BIOSCIENCES, INC. 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010
Oleg Nodelman director 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Selby Blake Hawley officer: Chief Commercial Officer C/O KINDRED BIOSCIENCES, INC. 1499 BAYSHORE HIGHWAY, SUITE 226 BURLINGAME CA 94010
Stephen S Galliker officer: Chief Financial Officer 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Kevin Schultz officer: Chief Scientific Officer C/O KINDRED BIOSCIENCES, INC. 1499 BAYSHORE HIGHWAY, SUITE 226 BURLINGAME CA 94010

Kindred Biosciences (Kindred Biosciences) Headlines

From GuruFocus

Steven Cohen Adopts Stake in Kindred Biosciences

By Sydnee Gatewood Sydnee Gatewood 04-02-2021